This site is intended for healthcare professionals
Abstract digital waveforms in blue and purple
FDA Drug information

Ipratropium Bromide

Read time: 1 mins
Marketing start date: 23 Dec 2024

Summary of product characteristics


Effective Time

20160614

Version

12

Spl Product Data Elements

Ipratropium Bromide Ipratropium Bromide BENZALKONIUM CHLORIDE EDETATE CALCIUM DISODIUM HYDROCHLORIC ACID WATER SODIUM CHLORIDE SODIUM HYDROXIDE HYDROXYETHYL CELLULOSE (140 MPA.S AT 5%) IPRATROPIUM BROMIDE IPRATROPIUM IPRATROPIUM BROMIDE ANHYDROUS

Application Number

ANDA076664

Brand Name

Ipratropium Bromide

Generic Name

Ipratropium Bromide

Product Ndc

0054-0045

Product Type

HUMAN PRESCRIPTION DRUG

Route

NASAL

Package Label Principal Display Panel

PACKAGE/LABEL PRINCIPAL DISPLAY PANEL NDC 0054- 0045 -44 30 mL (345 metered sprays) Ipratropium Bromide Nasal Solution / Nasal Spray 0.03% 21 mcg/spray Rx only 0.03% bottle label

Spl Unclassified Section

ATTENTION PHARMACISTS: Detach “Patient’s Instructions for Use” from package insert and dispense with product.

Spl Unclassified Section Table

Table 1: % of Patients Reporting Events+

Ipratropium Bromide Nasal Spray 0.03%

(n=356)

Vehicle Control

(n=347)

Incidence

%

Discontinued

%

Incidence

%

Discontinued

%

Headache

9.8

0.6

9.2

0.0

Upper respiratory tract infection

9.8

1.4

7.2

1.4

Epistaxis1

9.0

0.3

4.6

0.3

Rhinitis*

Nasal dryness

5.1

0.0

0.9

0.3

Nasal irritation2

2.0

0.0

1.7

0.6

Other nasal symptoms3

3.1

1.1

1.7

0.3

Pharyngitis

8.1

0.3

4.6

0.0

Nausea

2.2

0.3

0.9

0.0

+ This table includes adverse events which occurred at an incidence rate of at least 2.0% in the Ipratropium Bromide group and more frequently in the Ipratropium Bromide group than in the vehicle group.

1 Epistaxis reported by 7.0% of Ipratropium Bromide patients and 2.3% of vehicle patients, blood-tinged mucus by 2.0% of Ipratropium Bromide patients and 2.3% of vehicle patients.

2 Nasal irritation includes reports of nasal itching, nasal burning, nasal irritation, and ulcerative rhinitis.

3 Other nasal symptoms include reports of nasal congestion, increased rhinorrhea, increased rhinitis, posterior nasal drip, sneezing, nasal polyps, and nasal edema.

* All events are listed by their WHO term; rhinitis has been presented by descriptive terms for clarification.

Information For Patients

PATIENT’S INSTRUCTIONS FOR USE Ipratropium Bromide Nasal Solution, 0.03% Nasal Spray, 21mcg/spray Read complete instructions carefully before using. In order to ensure proper dosing, do not attempt to change the size of the spray opening. Ipratropium bromide nasal solution, 0.03% is indicated for the symptomatic relief of rhinorrhea (runny nose) associated with allergic and nonallergic perennial rhinitis in adults and children age 6 years and older. Ipratropium bromide nasal solution, 0.03% does not relieve nasal congestion, sneezing, or postnasal drip associated with allergic or nonallergic perennial rhinitis. Read complete instructions carefully and use only as directed. To Use: 1. Remove the clear plastic dust cap and the green safety clip from the nasal spray pump ( Figure 1 ). The safety clip prevents the accidental discharge of the spray in your pocket or purse. Figure 1 Figure 1 2. The nasal spray pump must be primed before ipratropium bromide nasal solution, 0.03% is used for the first time. To prime the pump, hold the bottle with your thumb at the base and your index and middle fingers on the white shoulder area. Make sure the bottle points upright and away from your eyes. Press your thumb firmly and quickly against the bottle seven times ( Figure 2 ). The pump is now primed and can be used. Your pump should not have to be reprimed unless you have not used the medication for more than 24 hours; repriming the pump will only require two sprays. If you have not used your nasal spray for more than seven days, repriming the pump will require seven sprays. Figure 2 Figure 2 3. Before using ipratropium bromide nasal solution, 0.03%, blow your nose gently to clear your nostrils if necessary. 4. Close one nostril by gently placing your finger against the side of your nose, tilt your head slightly forward and, keeping the bottle upright, insert the nasal tip into the other nostril ( Figure 3 ). Point the tip toward the back and outer side of the nose. Figure 3 Figure 3 5. Press firmly and quickly upwards with the thumb at the base while holding the white shoulder portion of the pump between your index and middle fingers. Following each spray, sniff deeply and breathe out through your mouth. 6. After spraying the nostril and removing the unit, tilt your head backwards for a few seconds to let the spray spread over the back of the nose. 7. Repeat steps 4 through 6 in the same nostril. 8. Repeat steps 4 through 7 in the other nostril (i.e., two sprays per nostril). 9. Replace the clear plastic dust cap and safety clip. 10. At some time before the medication is completely used up, you should consult your physician or pharmacist to determine whether a refill is needed. You should not take extra doses or stop using ipratropium bromide nasal solution, 0.03% without consulting your physician. To Clean: If the nasal tip becomes clogged, remove the clear plastic dust cap and safety clip. Hold the nasal tip under running, warm tap water ( Figure 4 ) for about a minute. Dry the nasal tip, reprime the nasal spray pump (step 2 above), and replace the plastic dust cap and safety clip. Figure 4 Figure 4 Caution: Ipratropium bromide nasal solution, 0.03% is intended to relieve your rhinorrhea (runny nose) with regular use. It is therefore important that you use ipratropium bromide nasal solution, 0.03% as prescribed by your physician. For most patients, some improvement in runny nose is usually apparent during the first full day of treatment with ipratropium bromide nasal solution, 0.03% Some patients may require up to two weeks of treatment to obtain maximum benefit. Do not spray ipratropium bromide nasal solution, 0.03% in your eyes. Should this occur, immediately flush your eye with cool tap water for several minutes. If you accidentally spray ipratropium bromide nasal solution, 0.03% in your eyes, you may experience a temporary blurring of vision, visual halos or colored images in association with red eyes from conjunctival and corneal congestion, development or worsening of narrow-angle glaucoma, pupil dilation, or acute eye pain/discomfort, and increased sensitivity to light, which may last a few hours. Should acute eye pain or blurred vision occur, contact your doctor. Should you experience excessive nasal dryness or episodes of nasal bleeding contact your doctor. If you have glaucoma or difficulty urinating due to an enlargement of the prostate, be sure to tell your physician prior to using ipratropium bromide nasal solution, 0.03% If you are pregnant or you are breast feeding your baby, be sure to tell your physician prior to using ipratropium bromide nasal solution, 0.03% Storage Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Avoid freezing. Keep out of reach of children. Address medical inquiries to Hikma Pharmaceuticals USA Inc. at 1-800-962-8364. Distributed by: Hikma Pharmaceuticals USA Inc. Berkeley Heights, NJ 07922 C50000619/01 Revised July 2022 figure-1.jpg figure-2.jpg figure-3.jpg figure-4.jpg

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Disclaimer

The drug Prescribing Information (PI), including indications, contra-indications, interactions, etc, has been developed using the U.S. Food & Drug Administration (FDA) as a source (www.fda.gov).

Medthority offers the whole library of PI documents from the FDA. Medthority will not be held liable for explicit or implicit errors, or missing data.

Drugs appearing in this section are approved by the FDA. For regions outside of the United States, this content is for informational purposes only and may not be aligned with local regulatory approvals or guidance.